维普中文期刊产品整合服务
245篇 您的检索式:作者名="TIM A"
    题名 作者 年代 出处 被引量
1Transarterial chemoembolization and bland embolization for hepatocellular carcinoma显示文摘Transarterial chemoembolization(TACE)is the first line treatment for patients with intermediate stage hepatocellular carcinoma but is also increasingly being used for patients on the transplant waiting list to prevent further tumor growth.Despite its widespread use,TACE remains an unstandardized procedure,with variation in type and size of embolizing particles,type and dose of chemotherapy and interval between therapies.Existing evidence from randomized controlled trials suggest that bland transarterial embolization(TAE)has the same efficacy with TACE.In the current article,we review the use of TACE and TAE for hepatocellular carcinoma and we focus on the evidence for their use.Emmanuel A Tsochatzis Evangelia Fatourou James O'Beirne Tim Meyer Andrew K Burroughs 2014World Journal of Gastroenterology2014,20,12:18
2Retrospective study on mixed neuroendocrine non-neuroendocrine neoplasms from five European centres显示文摘BACKGROUND Mixed neuroendocrine non-neuroendocrine neoplasm(MiNEN)is a rare diagnosis,mainly encountered in the gastro-entero-pancreatic tract.There is limited knowledge of its epidemiology,prognosis and biology,and the best management for affected patients is still to be defined.AIM To investigate clinical-pathological characteristics,treatment modalities and survival outcomes of a retrospective cohort of patients with a diagnosis of MiNEN.METHODS Consecutive patients with a histologically proven diagnosis of MiNEN were identified at 5 European centres.Patient data were retrospectively collected from medical records.Pathological samples were reviewed to ascertain compliance with the 2017 World Health Organisation definition of MiNEN.Tumour responses to systemic treatment were assessed according to the Response Evaluation Criteria in Solid Tumours 1.1.Kaplan-Meier analysis was applied to estimate survival outcomes.Associations between clinical-pathological characteristics and survival outcomes were explored using Log-rank test for equality of survivors functions(univariate)and Cox-regression analysis(multivariable).RESULTS Sixty-nine consecutive patients identified;Median age at diagnosis:64 years.Males:63.8%.Localised disease(curable):53.6%.Commonest sites of origin:colon-rectum(43.5%)and oesophagus/oesophagogastric junction(15.9%).The neuroendocrine component was;predominant in 58.6%,poorly differentiated in 86.3%,and large cell in 81.25%,of cases analysed.Most distant metastases analysed(73.4%)were occupied only by a poorly differentiated neuroendocrine component.Ninety-four percent of patients with localised disease underwent curative surgery;53%also received perioperative treatment,most often in line with protocols for adenocarcinomas from the same sites of origin.Chemotherapy was offered to most patients(68.1%)with advanced disease,and followed protocols for pure neuroendocrine carcinomas or adenocarcinomas in equal proportion.In localised cases,median recurrence free survival(RFS);14.0 months(95%CI:9.2-24.4),and median overall survival(OS):28.6 months(95%CI:18.3-41.1).On univariate analysis,receipt of perioperative treatment(vs surgery alone)did not improve RFS(P=0.375),or OS(P=0.240).In advanced cases,median progression free survival(PFS);5.6 months(95%CI:4.4-7.4),and median OS;9.0 months(95%CI:5.2-13.4).On univariate analysis,receipt of palliative active treatment(vs best supportive care)prolonged PFS and OS(both,P<0.001).CONCLUSION MiNEN is most commonly driven by a poorly differentiated neuroendocrine component,and has poor prognosis.Advances in its biological understanding are needed to identify effective treatments and improve patient outcomes.Melissa Frizziero Xin Wang Bipasha Chakrabarty Alexa Childs Tu V Luong Thomas Walter Mohid S Khan Meleri Morgan Adam Christian Mona Elshafie Tahir Shah Annamaria Minicozzi Wasat Mansoor Tim Meyer Angela Lamarca Richard A Hubner Juan W Valle Mairéad G McNamara 2019World Journal of Gastroenterology2019,25,39:13
3Direct ex vivo analysis of dendritic cells in patients with hepatocellular carcinoma显示文摘瞄准:与肝细胞癌(HCC ) 从病人分析树枝状的房间(DC ) 的显型和功能以便在这疾病理解他们的角色。方法:骨髓的的树枝状的房间在 HCC 病人的外部血被枚举。从外部血的天真、刺激的骨髓的的树枝状的房间上的 CD80, CD83, CD86 和 HLA 医生表示被分析。骨髓的的树枝状的房间从外部血被孤立,他们的功能被测试。吞噬作用用 FITC 葡聚糖祷告被分析,肽特殊刺激,在多形核白细胞 dI:dC 之上刺激 allogeneic T 房间和 cytokines 的分泌物的能力被测试。结果:骨髓的的树枝状的房间与 HCC 在病人被减少。在 CD80, CD83, CD86 和 HLA 医生表示的差别都没从 HCC 病人和健康控制在天真、刺激的骨髓的的树枝状的房间上被发现。肽 specific T 房间的正常吞噬作用或刺激与一个损害 allo-stimulatory 能力和减少的 IL-12 分泌物相对照被观察。结论:在病人的 mDCs 的损害 IL-12 生产能导致建议指导治疗可以提高的那 IL-12 的天真的 T 房间的一个损害 stimulatory 能力在 HCC 病人的肿瘤 specific 免疫者回答。Lars A Ormandy Anatol Frber Tobias Cantz Susanne Petrykowska Heiner Wedemeyer Monique Hrning Frank Lehner Michael P Manns Firouzeh Korangy Tim F Greten 2006World Journal of Gastroenterology2006,12,20:12
4乙肝病毒A1762、G1764双突变是筛选男性HBsAg携带者肝癌最高危人群的生物学标记显示文摘目的探讨乙肝病毒A1762、G1764双突变是否可作为筛选HBsAg携带者肝癌最高危人群的生物学标记。方法对2 258名乙肝病毒无症状携带者进行前瞻性队列研究,其中HBV A1762、G1764双突变株组1 261人,野毒株组997人,跟踪随访队列,每6个月1次对观察对象抽血进行甲胎蛋白(AFP)检测及B超体检以检查肝癌发病情况。结果观察48个月,2 258名乙肝病毒无症状携带者中,共发生肝癌72例,突变株组64例,野毒株组8例,发病率分别为932.2/10万人年和203.5/10万人年,两组发病率差异有统计学意义(P<0.001),相对危险度(RR)为4.58。突变株组男性发病率1 827.8/10万人年,明显高于野毒株组的180.5/10万人年,两者比较差异有统计学意义(P<0.001),相对危险度为10.13。92.5%的男性病例有双突变;突变株组女性发病率为686.6/10万人年,高于野毒株组的233.3/10万人年,两组比较差异有统计学意义(P<0.05),但相对危险度仅为2.94。结论双突变是筛选男性HBsAg携带者中肝癌最高危人群的很好生物学标记,但对女性筛选肝癌高危人群的意义不如男性。王学燕 李国坚 董柏青 杨进业 陈钦艳 方孔雄 黄坚 韦少超 方钟燎 Caroline A Sabin Tim J Harrison 2011广西医学2011,33,2:5
5隆安县乙肝病毒无症状携带者HBV前S基因缺失突变的研究显示文摘目的了解肝癌高发区隆安县乙型肝炎病毒(HBV)前S基因缺失突变株的流行情况。方法HBV表面抗原(HBsAg)无症状携带者从我们隆安县研究队列中选择,用套式聚合酶链反应对研究对象血清HBV前S基因扩增和序列分析。结果在66例标本中9例出现前S基因缺失突变,占13.6%(9/66)。9例缺失突变均为框内突变,其中7例突变发生在或涉及前S2区的5'末端。男6例、女3例出现前S基因缺失突变,但男女间突变率(12.0%,6/50与18.8%,3/16)差异无统计学意义(χ2=0.709,P>0.10);前S基因缺失突变率在基因型B、基因型C和重组基因型之间差异无统计学意义(χ2=0.002,P>0.95)。结论肝癌高发区隆安县居民HBV无症状携带者前S基因缺失突变率较高,这种突变与肝癌的关系值得进一步探讨。王学燕 李国坚 董柏青 陈钦艳 方孔雄 杨进业 黄坚 韦少超 方钟燎 Caroline A Sabin Tim J Harrison 2010广西医学2010,32,2:4
6Gemcitabine-based or capecitabine-based chemoradiotherapy for locally advanced pancreatic cancer (SCALOP): a multicentre, randomised, phase 2 trial显示文摘Somnath Mukherjee Christopher N Hurt John Bridgewater Stephen Falk Sebastian Cummins Harpreet Wasan Tom Crosby Catherine Jephcott Rajarshi Roy Ganesh Radhakrishna Alec McDonald Ruby Ray George Joseph John Staffurth Ross A Abrams Gareth Griffiths Tim Maugh 2013Lancet Oncology2013,,4:4
7Perforated jejunal ulcer associated with gastric mucosa in a jejunal diverticulum显示文摘Jejunal diverticula are rare and subsequent complications even more so. The usual small bowel diverticulum encountered by general surgeons is a Meckel's. These are embryological remnants of the vitello-intestinal duct and are on the anti-mesenteric surface of the terminal ileum. They may contain heterotopic gastric or pancreatic mucosa. Herein we explore the case of a young girl who presented with features of peritonitis secondary to a complication from a jejunal diverticulum. The case, pathology, complications and treatment of jejunal diverticulosis and heterotopic gastric mucosa in the jejunum are explored.John Bunni Helen L Barrett Tim A Cook 2014World Journal of Clinical Cases2014,2,6:2
8Pathological grading of regression following neoadjuvant chemoradiation therapy: the clinical need is now显示文摘Tom P MacGregor Tim S Maughan Ricky A Sharma 2012Journal of Clinical Pathology2012,,10:2
9HBsAg携带者配偶乙型肝炎病毒感染状况调查显示文摘目的了解广西乙型肝炎病毒(HBV)性传播状况。方法对我们2004年建立的隆安研究队列HBsAg无症状携带者的配偶采静脉血收集血清,用酶联免疫吸附试验检测HBV血清学标志物。结果 217名研究对象中,96.8%(210/217)有过去或目前感染乙肝病毒的标记,其中32例HBsAg阳性,阳性率为14.7%(32/217),男、女阳性率分别为15.4%(14/91)和14.3%(18/126),差异无统计学意义(χ2=0.051,P>0.05);107例HBsAb阳性,阳性率为49.3%(107/217);一名男性HBsAg和HBsAb同时阳性;有79例HBsAg,anti-HBs and HBeAg阴性,这79例要么抗-HBc和抗-HBe同时阳性,要么单项阳性,但都是HBVDNA阴性;有7人(包括男性3人、女性4人)没有任何乙肝感染标记,包括HBVDNA阴性。另外,122名HBVDNA阳性的HBsAg携带者其配偶(研究对象)有14人HBsAg阳性;95名HBVDNA阴性的HBsAg携带者其配偶有18人HBsAg阳性,两者阳性率无统计学差异(χ2=2.372,P>0.05)。HBeAg阴、阳性的HBsAg携带者其配偶的HBsAg阳性率分别为15.61%(27/173)和11.76%(4/34),两者也无统计学差异(χ2=0.093,P>0.05)。结论配偶因密切接触HBsAg携带者而受HBV感染的机会比一般人群大,但性别、病毒量和HBeAg不影响其配偶感染HBV的机会。王学燕 李国坚 杨进业 陈钦艳 黄坚 方孔雄 方钟燎 Caroline A Sabin Tim J Harrison 2010应用预防医学2010,16,6:2
10EU-Citizen.Science:A Platform for Mainstreaming Citizen Science and Open Science in Europe显示文摘Citizen Science(CS)is a prominent field of application for Open Science(OS),and the two have strong synergies,such as:advocating for the data and metadata generated through science to be made publicly available[1];supporting more equitable collaboration between different types of scientists and citizens;and facilitating knowledge transfer to a wider range of audiences[2].While primarily targeted at CS,the EU-Citizen.Science platform can also support OS.One of its key functions is to act as a knowledge hub to aggregate,disseminate and promote experience and know-how;for example,by profiling CS projects and collecting tools,resources and training materials relevant to both fields.To do this,the platform has developed an information architecture that incorporates the public participation in scientific research(PPSR)-Common Conceptual Model.This model consists of the Project Metadata Model,the Dataset Metadata Model and the Observation Data Model,which were specifically developed for CS initiatives.By implementing these,the platform will strengthen the interoperating arrangements that exist between other,similar platforms(e.g.,BioCollect and SciStarter)to ensure that CS and OS continue to grow globally in terms of participants,impact and fields of application.Katherin Wagenknecht Tim Woods Francisco García Sanz Margaret Gold Anne Bowser Simone Rüfenacht Luigi Ceccaroni Jaume Piera 2021Data Intelligence2021,3,1:2
11乙型肝炎病毒前S缺失突变与肝癌关系的巢式匹配病例对照研究显示文摘目的了解乙型肝炎病毒(HBV)前S基因缺失突变是否是肝癌的危险因素以及它的作用是否受HBV核心基因启动子双突变的混淆影响。方法按巢式匹配病例对照研究的方法,从隆安研究队列中选择33对病例(肝癌患者)和对照(HBsAg无症状携带者),配对的条件之一是病例和对照HBV核心基因启动子序列相同,用套式聚合酶链反应(nested PCR)对研究对象血清HBV前S基因扩增和序列分析。结果肝癌患者组前S基因缺失突变率(45.5%,15/33)显著高于对照组(6/33,18.2%)(χ2=7.364,P<0.01);男女间突变率无显著性差异(28%与43.8%,χ2=1.386,P>0.05)。多因素条件logistic回归分析结果显示,前S缺失突变是肝癌的危险因素(危险比为7,95%可信区:0.861-56.894),而HBeAg,抗-HBe及肝功能则与肝癌无关。核心基因启动子双突变组与核心基因启动子野毒株组之间的前S缺失突变率无显著性差异(χ2=0.597,P>0.05)。结论HBV前S缺失突变是肝癌的独立的危险因素,它的发生及作用与核心基因启动子双突变无关。王学燕 李国坚 董柏青 陈钦艳 方孔雄 杨进业 黄坚 韦少超 方钟燎 黄志碧 Caroline A Sabin Tim J Harrison 2010应用预防医学2010,16,1:2
12基于一个大型随机试验预测稳定性心绞痛队列患者死亡、心肌梗死和卒中的危险评分显示文摘目的对需要抗心绞痛治疗并且左心室功能代偿症状稳定的心绞痛患者建立预测全因死亡、心肌梗死和导致致残性卒中的复合危险评分。设计大型多中心临床试验数据的多变量Cox回归分析。背景西欧、以色列、加拿大、澳大利亚和新西兰的心脏专科门诊患者。入选者7311例具有全部需要资料的患者被入选。主要结局的测量指标平均随访4.9年时间内所有原因的死亡、心肌梗死或者致残性卒中。结果1063例患者发生任何原因死亡或者持久性心肌梗死或者致残性卒中。这些复合终点的5年危险性在危险性最低的十分位患者为4%,而在危险性最高的十分位患者为35%。危险评分结合16项临床常规变量的降序排序是:年龄、左心室射血分数、吸烟、白细胞计数、糖尿病、随机血糖浓度、肌酐浓度、既往卒中病史、1周至少1次心绞痛发作、冠状动脉造影发现(如果能够获得)、降脂治疗、QT间期、收缩期血压≥150mmHg、抗心绞痛药物数量、陈旧性心肌梗死以及性别。把这个模型分别应用于任何原因所致的死亡、心肌梗死和卒中进行预测评估,所得的结果相似。危险评分似乎不能预测事件性质(39%的死亡、46%心肌梗死以及15%致残性卒中)或者冠状动脉造影或血管重建率(占29%的患者)。结论该危险评分对客观地决定稳定性心绞痛患者进一步治疗措施以减少重要预后事件发生是有帮助的。该危险评分同样可以用于将来的计划性试验。Tim C Clayton Stuart J Pocock Jacobus Lubsen Zoltán Vokó Bridget-Anne Kirwan Keith A A Fox Philip A Poole-Wilson 2006英国医学杂志中文版2006,9,1:2
13Pharmaceutical Interventions for the Management of No-Reflow显示文摘Tim A 2008J Invasive Cardiol2008,20,7:1
14Fuel Consumption Minimization of a Microgrid 显示文摘Carlos A Hernandez-Arambur Tim C Green Nicolas Mugniot 2005IEEE Transactions on Industry Applications2005,41,3:1
15Mobilization and homing of bone marrow stromal cells in myocardial infarction显示文摘Bittira B Shum - Tim D Al - Khaldi A 2003Eur J Cardiothorac Surg2003,24,3:1
16Durability of an extruded HDPE/wood composite 显示文摘David E Pendleton Theresa A Hoffard Tim Adcock 2002Forest Products Journal2002,52,6:1
17Do Long-Term Shareholders Benefit from Corporate Acquisitions? 显示文摘Tim L Vijh A M 1997Journal of Finance1997,52,5:1
18Creation of viable pulmonary artery autografts through tissue engineering显示文摘Shinoka T Tim A D Ma P X 1998J Thorac Cardiovas Surg1998,115,:1
19Assessment of sediment and porewater after one year of sub aqueous capping of contaminated sediments in Hamilton Harbour, Canada显示文摘Azcue J M Zeman A J Alena Mudroch Fernando Rosa Tim Patterson 1998Wat Sci Tech1998,37,67:1
20Positive interpretation training:Effects of mental imagery versus verbal training on positive mood显示文摘Emily A Holmes Andrew Mathews Tim Dalgleish Bundy Mackintosh 0,,03:1
返回顶部 每页显示:
共13页 首页 上一页 第1页 下一页 末页 /13 跳转

网站首页 | 关于我们 | 联系我们 | 产品服务 | 客服中心 | 广告服务 | 版权声明 | 网站联盟 | 友情链接 | 售卡网点

版权所有© 渝B2-20050021-1 渝公网安备 50019002500403号 违法和不良信息举报中心

互联网出版许可证 新出网证(渝)字10号 全国400电话 - 免长途话费